A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters-Yonhap
COPENHAGEN — Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc's medicines regulator said on Friday.
The European Medicines Agency said it had "recommended an extension to the marketing authorization for Wegovy (semaglutide) in the EU to add an oral formulation for weight management", alongside the injectable treatment.
The decision follows U.S. approval of the pill form in December.
Novo Nordisk says prescriptions there have surged to over 200,000 a week.
